COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

The Europe Continuous Glucose Monitoring Device Market would witness market growth of 12% CAGR during the forecast period (2020-2026).
Continuous glucose monitors (CGMs) are widely available and efficient as a tool for real-time biofeedback and behavioral improvement for individuals with type 2 diabetes (T2D), and also those with prediabetes. A convergence of many megatrends in healthcare will lead to the ever more frequent use of CGM in people with T2D and even prediabetes. This will also further boost the precision, size, and cost of CGM; include the option to transfer data to the cloud. The integration will ensure the availability of digital coaching methods and computational applications, and eventually, artificial intelligence and a change to value-based treatment will follow.
Growing cases of diabetes have accelerated the market, along with the rising use of continuous glucose monitoring (CGM) devices. CGM devices are minimally invasive and provide a simple and reliable approach to diabetes treatment. They can also track dramatic changes in levels of blood glucose, thereby avoiding hypoglycemic disorders.
Through the assistance of a sensor, these instruments enable the analysis of blood glucose levels at different time intervals. Respective readings fed in via a wireless network to a diabetes treatment software allow patients to better understand the condition, thereby allowing them to treat it more effectively.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study
Market Segmentation:
By Component

  • Sensors
  • Transmitters and
  • Receivers


By End User

  • Hospitals
  • Homecare Settings and
  • Other End Users


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • Abbott Laboratories
  • Medtronic PLC
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • DexCom, Inc.
  • Ypsomed AG
  • Senseonics Holdings, Inc.
  • GlySens, Incorporated
  • A. Menarini Diagnostics Ltd. (The Menarini Group)
  • Echo Therapeutics, Inc.
  • Johnson and Johnson


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free